Replimune Group Investor Relations Material

Replimune Group Inc. is a biotechnology company focused on the development of oncolytic immunotherapies for the treatment of cancer. The company leverages its proprietary Immulytic platform to engineer viruses that selectively replicate within tumors, stimulating an immune response to attack the cancer cells. Replimune's therapies are designed to be used in combination with other immuno-oncology treatments to enhance their effectiveness. The company targets various forms of cancer, aiming to improve outcomes for patients with difficult-to-treat malignancies. The company is headquartered in Woburn, Massachusetts, and its shares are listed on the NASDAQ.